|Application ||WB, IHC-P, E|
|Other Accession||NP_001074317.2, NP_001123300.1, NP_001123298.1, NP_004900.2|
|Calculated MW||14430 Da|
|Antigen Region||1-30 aa|
|Other Names||Chondrosarcoma-associated gene 2/3 protein, Cancer/testis antigen 242, CT242, Taxol-resistant-associated gene 3 protein, TRAG-3, CSAG2, TRAG3|
|Target/Specificity||This CSAG2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human CSAG2.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||CSAG2 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Drug-resistance related protein, its expression is associated with the chemotherapy resistant and neoplastic phenotype. May also be linked to the malignant phenotype.|
|Tissue Location||Weakly expressed in kidney. Expressed in various tumor cell lines including carcinomas, myeloid and lymphoid malignancies, melanomas and prostate cancer Overexpressed in taxol-resistant breast cancer line MDA 435TR and the doxorubicin-resistant multiple myelanoma lines RPMI-8226/Dox40 and RPMI-8226/MDR10V|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Hansen, M.A., et al. Mol. Reprod. Dev. 75(2):219-229(2008)
Janjic, B., et al. J. Immunol. 177(4):2717-2727(2006)
Ohta, M., et al. Oncol. Rep. 15(6):1529-1532(2006)
Yao, X., et al. Cancer Genet. Cytogenet. 151(1):1-13(2004)
Lin, C., et al. Gene 285 (1-2), 269-278 (2002) :
Venter, J.C., et al. Science 291(5507):1304-1351(2001)
Feller, A.J., et al. Anticancer Res. 20 (6B), 4147-4151 (2000) :
Duan, Z., et al. Gene 229 (1-2), 75-81 (1999) :
If you have any additional inquiries please email technical services at email@example.com.